The European Medicines Agency (EMA) has approved two monoclonal antibodies, Regkirona (regdanvimab) and Ronapreve (casirivimab / imdevimab), as biological drugs in the fight against COVID-19. Both drugs will be given to patients who do not require additional oxygen but are at high risk of developing severe COVID-19.